A new field study mapped three distinct joint-smoking styles—and each pulls more smoke than cigarette lab settings. Here’s what that means for dosing, safety, and DMV consumers.

A national program elevating evidence-informed cannabis safety and medical access closes public nominations Sept. 10, with finalists Sept. 14 and winners Sept. 30.

THCa vapes are reshaping cannabis use with fast onset, discretion, and tech-forward devices. Here’s the science, safety, and what it means for DC, Maryland, and Virginia.

Half of Kentucky’s licensed dispensaries are now open, patient registrations have surpassed 25,000, and monthly sales are rising—signaling expanding access across the state.

What cannabigerol (CBG) is, why scientists call it cannabis’s precursor cannabinoid, what preclinical research suggests, and how DMV patients should approach it today.

A new driving-simulator study found no intoxication or cognitive impairment from 15–1,500 mg CBD. Here’s what that means for patients, drivers, and DMV consumers.

Disabled and autistic participants face distinct physiological and sensory needs during psychedelic work. Here’s how to make ceremonies safer—and what DMV readers should know.

Explore how employer-sponsored medical cannabis benefits are cutting healthcare costs, backed by clinical research and DMV access updates.

Discover how plant pigments and cannaflavins shape flavor, therapeutic effects, and the future of full-spectrum cannabis science.

A Brazilian team reported caregiver-rated improvements after individualized full-spectrum cannabis extracts in 20 ASD patients, with small-sample limits and no control group.

NORML reports a pediatric clinical trial found a plant-derived cannabis preparation was safe and effective for autism, with disease severity falling about 2 points on a 7‑point scale after eight weeks.

What science says about terpenes, how they shape cannabis effects with cannabinoids, and what this means for patients and consumers in DC, Maryland and Virginia.

NORML’s op-ed argues cannabis does not share the health risks of heroin, cigarettes, or alcohol and calls for removing it from Schedule I. Here’s what that stance means.

An evidence-based analysis of drug war myths, fentanyl cannabis claims, harm reduction data, and Virginia marijuana laws.

A federally funded study of 65 cancer patients links symptom relief to THC/CBD profiles and highlights stigma and high costs—fueling calls to insure medical cannabis.

Washington State University researchers examine how social media advertising influences young adults' expectations and behavioral choices around intimate cannabis use.

Johns Hopkins researchers put 25 mg oral THC to the test against psilocybin, offering fresh insights for DMV cannabis consumers.

A deep dive into Ren and Chris Webby's collaborative album Asylum, examining its studio lore, pharmaceutical commentary, and scientific themes.

Americans for Safe Access brings together leaders to address patient access, evidence-based policy, and regulatory enforcement.

The official record for the DEA's landmark cannabis rescheduling hearing required 294 corrections, with a few critical errors flipping witness statements on THC levels and public safety, a new report shows.